Human T leukaemia Type 1 and COVID-19

Araújo, Abelardo; Martin, Fabiola

doi:10.3390/pathogens9060438

Cited by 9 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19 in individuals with human T-cell lymphotropic virus 1 type-1 (HTLV-1) infection, and a need for guidance on management of patients with HTLV-1 and COVID-19 coinfection. 2 Herein, we report a fatal case of COVID-19 in a previously undiagnosed HTLV-1 carrier.…”

mentioning

confidence: 93%

COVID‐19 in a human T‐cell lymphotropic virus type‐1 carrier

Enomoto

Shiroyama

Hirata

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 93%

COVID‐19 in a human T‐cell lymphotropic virus type‐1 carrier

Enomoto

Shiroyama

Hirata

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…With the advent of the COVID-19 pandemic and governmental guidelines recommending social distancing, EBMSP implemented a contingency plan for employees, students, and patients [ 15 ], which made it impossible for patients to be seen at CHTLV. Despite the fact that no reports have indicated that COVID-19 may be more severe in patients infected with HTLV-1, special care recommendations have been published for this group, since this infection predominantly affects older individuals for whom comorbidities such as diabetes, systemic arterial hypertension, and overweight are frequent [ 16 ]. Moreover, it has been reported that HTLV-1-infected individuals may present some degree of immunosuppression, since several infectious diseases, such as tuberculosis, strongyloidiasis, and scabies, are more frequent or more severe in these individuals [ 9 ].…”

Section: Case Presentationmentioning

confidence: 99%

Challenges in establishing telehealth care during the COVID-19 pandemic in a neglected HTLV-1-infected population in northeastern Brazil

et al. 2020

View full text Add to dashboard Cite

“…This information is still scarce and is under study. 11 This article will explain the experience during these two years of the pandemic with HTLV-1 patients in our cohort and concomitant SARS-CoV-2 infection in this type of patient.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 (COVID-19) infection in patients with HTLV-1 infection in Peru - case series

Gotuzzo¹,

Nakazaki²,

Cordero³

et al. 2023

JHVRV

View full text Add to dashboard Cite

Introduction: Peru has suffered a prolonged sanitary emergency and has the highest COVID – 19 mortalities per capita in the world. Some risk factors (diabetes, HIV, cardiovascular diseases, etc.) are currently considered by the CDC to develop severe COVID-19 infection. CDC considers as possible risk factors (evidence is mixed), other immunodeficiency conditions, one of them would be infection by HTLV-1 (human T-cell lymphotropic virus type 1). It is not known whether subjects with HTLV – 1 infection have a higher risk for severe COVID – 19 disease. Materials and methods: We identified 51 patients with HTLV-1 and COVID-19. The patients recruited for this article belong to the HTLV-1 cohort of the Institute of Tropical Medicine Alexander von Humboldt - Cayetano Heredia Hospital and to the study cohort: "The effect of Strongyloides Stercoralis on HTLV-1 disease progression”. Periodic telemedicine follow-up was carried out on our patients during the lockdown from April 2020 to November 2021, and information related to SARS-CoV-2 infection was recorded. Results: 51 patients from cohorts were diagnosed with COVID-19 during the pandemic between April 2020 and October 2021. The majority are female (29 patients, 56.85%). 76.47% (39 patients) underwent a molecular/PCR, antigenic or serological test; while 23.53% (12 patients) developed symptoms compatible with COVID-19 in a context of family outbreak and positive direct contact. 74.51% (38 patients) developed a mild form of the disease, 15.69% (8 patients) a moderate form and 9.80% (5 patients) were asymptomatic. The most frequent symptoms were general malaise and/or fever (82.35%), headache (80.39%) and cough (76.47%). Discussion: the course of SARS-CoV-2 in patients infected with HTLV-1 follows similar patterns in percentage and symptoms compared to the general population. 81% usually develop a mild condition, while for our data 74.51% did. 14% usually develop moderate to severe disease worldwide, in our cohort, 15.69% developed moderate disease. The patients show a clinical picture similar to what is described in the literature as a common presentation of SARS-CoV-2. American studies show that the most frequent symptoms are headache (76%) and sore throat (65%); in our cohort, 80.39% reported headache and 35.29% sore throat. Conclusion: Patients with HTLV-1 who become infected with SARS-CoV-2 develop mild or moderate disease in similar proportions to the general population. More studies are needed to elucidate the risk of developing severe SARS-CoV-2 disease in patients infected with HTLV-1 and its associated comorbidities.

show abstract

Human T leukaemia Type 1 and COVID-19

Abstract: In the absence of clinical data on Human T leukaemia Type 1 and COVID-19 infection, we are providing guidance to clinicians who look after people living with HTLV-1.

Cited by 9 publications

References 15 publications

COVID‐19 in a human T‐cell lymphotropic virus type‐1 carrier

COVID‐19 in a human T‐cell lymphotropic virus type‐1 carrier

Challenges in establishing telehealth care during the COVID-19 pandemic in a neglected HTLV-1-infected population in northeastern Brazil

SARS-CoV-2 (COVID-19) infection in patients with HTLV-1 infection in Peru - case series

Contact Info

Product

Resources

About